Effect of Electroacupuncture on Symptoms of Female Pelvic Organ Prolapse(Level II - III )
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 160
- Primary Endpoint
- the change from baseline on the score of the Pelvic Floor Distress Inventory-short form 20 (PFDI-20)
Study Overview
Brief Summary
The purpose of the study is to assess the efficacy and safety of electroacupuncture among women with pelvic organ prolapse(Level II - III), compared with sham electroacupuncture.
Detailed Description
After being informed about the study and potential risk, all patients giving written informed consent form will be undergo a 1-week screening period to determine eligibility for study entry. Eligible patients will be randomly assigned to one of the two groups 1) electroacupuncture group: electroacupuncture will be provided to patients at BL33, BL35 and SP6 for 3 time per week for the first 4 weeks, then twice a week for 4 weeks, and once a week for the last 4 weeks. There will be 24 times of treatment in total in 3 month; 2) sham electroacupuncture group: sham electroacupuncture will be provided to patients at sham acupoints to BL33, BL35 and SP6 with the same schedule as electroacupuncture group.The follow-up time for the two groups are 6 months after treatment. Primary and secondary outcome will be measured at 3, 6, and 9 months from the start of the treatment, respectively.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Masking Description
The participants, investigator and outcome assessor will be masked. The care provider cannot be masked, but will be different person from investigator and outcome assessor.
Eligibility Criteria
- Ages
- 35 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •female patients with pelvic organ prolapse at level 2-3 via POP-Q examination;
- •patients at the age of 35 years or older;
- •patients who have a sensation of bulging or protrusion from virginal area, with or without urinary, bowel, and sexual disorders;
- •patients who have a score of PFDI-20 >
- •Patients who have signed informed consent form and are willing to participate the study voluntarily.
- •Patients will be included if all above 5 items are met.
Exclusion Criteria
- •Patients who have cognitive disorders and cannot understand the content of questionnaires;
- •Patients who have severe heart, lung, brain, liver, kidney, hematopoietic system, and immune system diseases, or severe malnutrition;
- •Patients who have cancer or are at terminal stage of severe diseases;
- •Patients who need finger assistance for defecation, or have severe prolapse of rectum, sigmoid colon or small intestine;
- •Patients who have received(or are receiving) treatments for pelvic floor disorders , including pelvic organ prolapse, stress urinary incontinence, and etc in the past one month;
- •Patients who are receiving any treatment for other gynecological diseases;
- •Patients who have symptomatic urinary tract infection with urinary pain and urge, or have residual urine volume ≥ 100ml;
- •Patients who have diseases affecting the neurological function of pelvic organ, e.g. spinal cord injury, or peripheral nerve injury caused by surgery at lumbosacral area or pelvic floor .
- •Patients will be excluded if they meet any of the above criteria.
Arms & Interventions
electroacupuncture group
patients will receive electroacupuncture at 3 acupoints(Bladder meridian of foot-taiyang 33 and 35#BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 4 weeks, then 3 times/week for 4 weeks, and then once/week for 4 weeks(24 times in total in 3 months), and be followed up for 6 months after treatment. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 ×40 mm at SP 6. Standardized electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6.
Intervention: electroacupuncture (Other)
sham electroacupuncture group
patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz.
Intervention: sham electroacupuncture (Other)
Outcomes
Primary Outcomes
the change from baseline on the score of the Pelvic Floor Distress Inventory-short form 20 (PFDI-20)
Time Frame: at baseline, and 3 months when the treatment is completed.
Data will be collected via the the Pelvic Floor Distress Inventory-short form 20 (PFDI-20) . The questionnaire consists of three sections, pelvic organ prolapse distress inventory 6 (POPDI-6), colorectal-anal distress inventory 8 (CRADI-8), and urinary distress inventory 6 (UDI-6). Each section has 6-8 questions with 5 answers rated from 0-4 in each, and mean score of each section is the total score of this section divided by number of questions in this session. Then the sum of the mean scores of the three section timing 25 will come to the total score of the questionnaire(0-300). The higher the total score is, the severer the symptoms are.
Secondary Outcomes
- number of patients at different levels of pelvic organ prolapse quantitative examination(POP-Q)(at baseline, and 3 months when the treatment is completed.)
- the change from baseline on the score of the Pelvic Floor Impact Questionnaire Short Form-7（PFIQ-7）(at baseline, 3 months, 6 months and 9 months since the start of the treatment.)
- the change from baseline on the score of pelvic organ prolapse/urinary incontinence sexual questionnaire-12(PISQ-12)(at baseline, 3 months, 6 months and 9 months since the start of the treatment.)
- blinding assessment(in 12th week after any acupuncture treatment)
- the change from baseline on the score of the Pelvic Floor Distress Inventory-short form 20 (PFDI-20)(6 months and 9 months since the start of the treatment.)
- patients' expectation to the effect of treatment(at baseline, and 3 months when the treatment is completed.)
- incidence rate of any adverse events(3 months, 6 months and 9 months since the start of the treatment.)
- the change from baseline in the validated Chinese version of International Consultation on Incontinence Questionnaire- Short Form(ICIQ-SF) scores(at baseline, 3 months, 6 months and 9 months since the start of the treatment.)
- score of the patient global index of improvement (PGI-I)(at baseline, 3 months, and 9 months since the start of the treatment.)
Investigators
Liu Zhishun
Chief Physician, Dean of Acupuncture Department
Guang'anmen Hospital of China Academy of Chinese Medical Sciences